Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis-Reference-Cited by-同舟云学术

Cost-effectiveness of abatacept, tocilizumab and TNF-inhibitors compared with rituximab as second-line biologic drug in rheumatoid arthritis

Published:2019-07-24 Issue:7 Volume:14 Page:e0220142
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Huoponen Saara^ORCID,Aaltonen Kalle J.,Viikinkoski Jaana,Rutanen Jarno,Relas Heikki,Taimen Kirsi,Puolakka Kari,Nordström Dan,Blom Marja

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference43 articles.

1. Rheumatoid Arthritis (online). Current Care Guidelines. Working group set up by the Finnish Medical Society Duodecim and the Finnish Society for Rheumatology. 2015. Available from: http://www.kaypahoito.fi (accessed December 21, 2018).

2. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update;JS Smolen;Ann Rheum Dis,2017

3. Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis;KJ Aaltonen;PLoS One,2012

4. Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis;S Ramiro;Ann Rheum Dis,2014

5. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA;JL Nam;Ann Rheum Dis,2010

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Modelling the opportunity for cost-savings or patient access with biosimilar adalimumab and tocilizumab: a European perspective;Journal of Medical Economics;2024-07-23

2. Cost-effectiveness of tumor necrosis factor-alpha inhibitors: a systematic review and meta-analysis of cost-utility studies;Expert Review of Pharmacoeconomics & Outcomes Research;2023-08-28

3. Factors associated with selection of targeted therapy in patients with rheumatoid arthritis;PLOS ONE;2023-01-10

4. Cost Effectiveness of Rituximab Therapy for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Cost-Utility Studies;Clinical Drug Investigation;2023-01-09

5. Managing inadequate response to initial anti-TNF therapy in rheumatoid arthritis: optimising treatment outcomes;Therapeutic Advances in Musculoskeletal Disease;2022-01